ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C1269613 | null | Entire thumb|Entire thumb (body structure)|Entire pollux | Entire thumb |
C0005558 | Removal and pathologic examination of specimens from the living body. | biopsied|BX - Biopsy|Biopsy - action (qualifier value)|biopsies|Bx|BIOPSY|Biopsy|biopsy procedure|Biopsies|Biopsy - action|biopsy|Biopsy (procedure)|Biopsy, NOS | Biopsy |
C0002688 | The removal of a limb or other appendage or outgrowth of the body. (Dorland, 28th ed) | Amputations|Amputation, NOS|amputation|Amputation, not otherwise specified|amputations|Amputation - action (qualifier value)|AMPUTATION|amputation procedure|Amputation|Amputation (procedure)|Amputation - action | Amputation |
C0015813 | The hemispheric articular surface at the upper extremity of the thigh bone. (Stedman, 26th ed) | Heads, Femur|Head of femur|head femur|femur head|femoral heads|FEMORAL HEAD|head of femur|Femur Heads|femoral head|Head of the Femur|Femoral head|Caput femoris|femur head of|Femoral Head|Head, Femur|Femur Head|Structure of head of femur|Structure of head of femur (body structure)|Kopf des Schenkelbeins | Head of femur |
C0038250 | Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells. | Stem cell|cell progenitors|progenitor cells|Cell, Mother|Stem cells|Stem cell (cell)|Stem Cell|mother cell|stem cell|Cells, Progenitor|Mother Cell|Progenitor Cells|Progenitor Cell|cells progenitors|Stem Cells|cell progenitor|progenitor cell|cells stems|Mother Cells|stem cells|Cells, Mother|mother cells|hemocytoblasts|Cell, Progenitor|Cell, Stem|Mother cell|Cells, Stem|blast cells|blast cell|hemocytoblast | Stem cells |
C0677850 | Another treatment used together with the primary treatment. Its purpose is to assist the primary treatment. | adjuvant therapy|adjunct therapy|Adjuvant Therapy|adjunctive therapy | Adjuvant Therapy |
C0085533 | Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. | Adjuvant Chemotherapy|Drug Therapy, Adjuvant|Adjuvant Drug Therapy|adjuvant chemotherapy | Chemotherapy, Adjuvant |
C0023413 | The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. | L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid|Folinate|Acido folinico|Leukovorin|folinic acid|N-[p-[[(2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic acid|5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid|5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid|5-formyltetrahydrofolic acid|Acide folinique|leukovorin|Leukovorin preparation|Leukovorin rescue factor|Folinic acid-containing product|N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid|Folinic acid|Leucovorinum|5-formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid|LEUCOVORIN|citrovorum|5-Formyl-5,6,7,8-tetrahydrofolic Acid|L-Glutamic acid, N-(4-(((2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-|Folinic acid preparation|5-Formyl-5,6,7,8-tetrahydrofolic acid|Leucovorin preparation|N5-Formyltetrahydrofolic acid|acid folinic|N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid|Leucovorin|Product containing folinic acid (medicinal product)|Leukovorum|leucovorin|N5-Formyl-5,6,7,8-tetrahydrofolic acid|(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate|5-formyl-5,6,7,8-tetrahydrofolic acid|5-formyl tetrahydrofolate|5-Formyl tetrahydrofolate preparation|Folinic Acid|Folinic Acid SF|5-Formyl Tetrahydrofolate|Acid, Folinic|Folinic Acid-SF|Folinic acid (substance) | leucovorin |
C0728747 | A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed. | Monoclonal Antibody c-erb-2|Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer|Anti-ERB-2|TRASTUZUMAB|trastuzumab|Trastuzumab (substance)|Anti-p185-HER2|rhuMAb HER2|Anti-HER2/c-erbB2 Monoclonal Antibody|Anti-c-ERB-2|anti-ERB-2|HER2 monoclonal antibody|anti-HER2/c-erbB2 monoclonal antibody|c-erb-2 Monoclonal Antibody|Anti-erbB2 Monoclonal Antibody|Product containing trastuzumab (medicinal product)|monoclonal antibody HER2|monoclonal antibody c-erb-2|RHUMAB HER2|Trastuzumab|anti-erbB2 monoclonal antibody|Trastuzumab-containing product|MOAB HER2|Anti-c-erbB2 Monoclonal Antibody|Anti-erbB-2|HER2 Monoclonal Antibody|anti-c-erB-2|MoAb HER2|Monoclonal Antibody HER2|anti-c-erbB2 monoclonal antibody|anti-p185-HER2|anti-erbB-2 | trastuzumab |
C0728747 | A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed. | Monoclonal Antibody c-erb-2|Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer|Anti-ERB-2|TRASTUZUMAB|trastuzumab|Trastuzumab (substance)|Anti-p185-HER2|rhuMAb HER2|Anti-HER2/c-erbB2 Monoclonal Antibody|Anti-c-ERB-2|anti-ERB-2|HER2 monoclonal antibody|anti-HER2/c-erbB2 monoclonal antibody|c-erb-2 Monoclonal Antibody|Anti-erbB2 Monoclonal Antibody|Product containing trastuzumab (medicinal product)|monoclonal antibody HER2|monoclonal antibody c-erb-2|RHUMAB HER2|Trastuzumab|anti-erbB2 monoclonal antibody|Trastuzumab-containing product|MOAB HER2|Anti-c-erbB2 Monoclonal Antibody|Anti-erbB-2|HER2 Monoclonal Antibody|anti-c-erB-2|MoAb HER2|Monoclonal Antibody HER2|anti-c-erbB2 monoclonal antibody|anti-p185-HER2|anti-erbB-2 | trastuzumab |
C0000726 | That portion of the body that lies between the THORAX and the PELVIS. | Abdomen|abd|Abdomen, NOS|Structure of abdominopelvic cavity and/or content of abdominopelvic cavity and/or anterior abdominal wall|Intra-abdominopelvic structure and/or anterior abdominal wall|Abdomens|Structure of abdominopelvic cavity and/or content of abdominopelvic cavity and/or anterior abdominal wall (body structure)|Abdomen (volume)|abdominopelvic regions|Abdominopelvic region|ABDOMEN|Abdominopelvis|abdomen|Abdominal|abdominopelvic region|abdominal | Abdomen |
C0494165 | Cancer that has spread from the original (primary) tumor to the liver. | Malignant neoplasm of liver, secondary|Liver Metastasis|Liver metastasis|Secondary malignancy of liver|Malignant neoplasm of liver, specified as secondary|hepatic metastasis|liver metastases|Metastatic malignant neoplasm to liver|cancer, metastatic to liver|Metastatic Malignant Neoplasm in the Liver|LIVER CANCER, METASTATIC|Metastasis to liver|metastasis to liver|metastases to liver|Liver secondary cancer|Metastatic Neoplasm to the Liver|Liver secondaries|Metastatic Malignant Neoplasm to the Liver|Metastatic malignant neoplasm to liver, NOS|Metastases to liver, NOS|Secondary malignant neoplasm of liver (disorder)|Metastatic Tumor to the Liver|liver metastasis|secondary liver cancer|Cancer metastatic to liver|secondary cancer of liver|HEPATIC NEOPLASM SECONDARY|liver secondaries|hepatic metastases|Hepatic metastasis|metastatic cancer to liver|Secondary malignant neoplasm of liver, NOS|metastatic liver cancer|liver, metastatic cancer to|Liver Metastases | Secondary malignant neoplasm of liver |
C0677930 | A tumor at the original site of origin. | primary tumor|Primary Tumor|primary tumors|Primary Neoplasm | Primary Neoplasm |
C0048808 | A fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand. | 5'-dfur|5'-deoxy-5'-fluorouridine|5'-fluoro-5'-deoxyuridine|Doxifluridine|5'-DFUR|DOXIFLURIDINE|1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil|doxifluridine|doxyfluridine|5-fluoro-5'-deoxyuridine|uridine-5'-deoxy-5-fluoro-|Doxifluridinum|Doxifluridina|5'-Deoxy-5-fluorouridine|5'-deoxy-5-fluorouridine|5-DFUR | doxifluridine |
C0023413 | The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. | L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid|Folinate|Acido folinico|Leukovorin|folinic acid|N-[p-[[(2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic acid|5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid|5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid|5-formyltetrahydrofolic acid|Acide folinique|leukovorin|Leukovorin preparation|Leukovorin rescue factor|Folinic acid-containing product|N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid|Folinic acid|Leucovorinum|5-formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid|LEUCOVORIN|citrovorum|5-Formyl-5,6,7,8-tetrahydrofolic Acid|L-Glutamic acid, N-(4-(((2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-|Folinic acid preparation|5-Formyl-5,6,7,8-tetrahydrofolic acid|Leucovorin preparation|N5-Formyltetrahydrofolic acid|acid folinic|N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid|Leucovorin|Product containing folinic acid (medicinal product)|Leukovorum|leucovorin|N5-Formyl-5,6,7,8-tetrahydrofolic acid|(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate|5-formyl-5,6,7,8-tetrahydrofolic acid|5-formyl tetrahydrofolate|5-Formyl tetrahydrofolate preparation|Folinic Acid|Folinic Acid SF|5-Formyl Tetrahydrofolate|Acid, Folinic|Folinic Acid-SF|Folinic acid (substance) | leucovorin |
C0520484 | Transplantation between animals of different species. | Transplantation, Heterologous|Heterograft Transplantation|Transplantation, animal-human|Transplantation, xenogeneic|Xenograft Transplantation|Animal-human transplantation|Transplantation, Xenograft|Heterografting|Heterologous Transplantation|heterologous transplantation|Xenotransplantation|Xenogeneic transplantation (procedure)|Heterologous transplantation|xenografting|xenotransplantation|Xenografting|xenografts|Xenogeneic transplantation|xenograft|Transplantation, Heterograft | Xenograft procedure |
C0246415 | A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. | Docetaxel Hydrate|DOCETAXEL|Docetaxol|TXL|Docetaxel-containing product|docetaxel|Docetaxel Trihydrate|Product containing docetaxel (medicinal product)|[2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester|Docetaxel (substance)|[2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester|Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aR,6R,9S,11S,12S,12aS,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,4a ,6,11-tetrahydroxy-8,12a,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR)-, hydrate (1:3)|Docetaxel|DOCEtaxel|docetaxol | docetaxel |
C1172402 | null | TS-1 | TS-1 titanium silicide |
C0160390 | Damage to liver structure or function due to trauma or toxicity. | Injury of liver, NOS|Hepatic trauma|Hepatic injury, NOS|Injury to liver|Injury of liver (disorder)|of liver injury|injuries liver|injury hepatic|liver injury|Injury to Liver|Hepatic injury|injury liver|LIVER INJURY|hepatic trauma|hepatic injury | Injury of liver |
C0206061 | Inflammation of interstitial lung tissue, usually associated with infection. | Interstitial pneumonitis|Interstitial Pneumonitides|Interstitial Pneumonitis|interstitial pneumonia|INTERSTITIAL PNEUMONIA|INTERSTITIAL PNEUMONITIS|Interstitial pneumonia|Pneumonia, interstitial|Interstitial Pneumonias|interstitial pneumonias|interstitial pneumonitis|PNEUMONIA, INTERSTITIAL|Pneumonias, Interstitial|Pneumonitides, Interstitial|Interstitial pneumonia (disorder)|Interstitial Pneumonia|PNEUMONITIS, INTERSTITIAL|Pneumonia, Interstitial|Pneumonitis, Interstitial | Pneumonia, Interstitial |
C1527304 | An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures. | Allergic Reactions|Reactions, Allergic|Allergic reaction|Reaction, Allergic|Allergy|allergic response|Allergic reactions|Allergic reaction (disorder)|Allergic Reaction | Allergic Reaction |
C0024264 | White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. | Lymphocytes|Lymphocytic|Lymphocyte (cell)|Lymphocyte, NOS|Lymphocytic cell|lymph cell|Marrow lymphocyte|Lymph Cell|Blood lymphocyte|Lymphocyte|Blood lymphocytic cell|Lymphocytic cell, NOS|lymphocyte|lymphocytes | Lymphocyte |
C0013182 | Immunologically mediated adverse reactions to medicinal substances used legally or illegally. | allergy drugs|drugs hypersensitivity|Drug Hypersensitivity|Medicine allergy|allergy drug|Allergic reaction caused by drug (disorder)|allergies drugs|Allergic drug reaction|Allergy to drug (finding)|allergies drug|medication allergy|drug allergic reaction|Allergy to drug|Drug hypersensitivity NOS|Allergy to drugs|Drug Hypersensitivities|allergic drugs reactions|DRUG ALLERGY|allergic reaction to drug|Allergic reaction caused by drug|Hypersensitivity, Drug|drugs allergic reaction|allergies medication|Drug allergy NOS|allergic reaction drug|Allergies, Drug|Medication allergy|Hypersensitivities, Drug|Drug reaction, allergic|Drug Allergy|Allergic reaction to medication|allergic drug reactions|Drug Allergies|Drug allergy, NOS|allergic drugs reaction|allergic drug reaction|Drug allergy|drug allergies|drug allergy|allergy medication|allergy medications|Allergy, Drug|allergies medications|Allergic reaction to drug|drug hypersensitivity | Drug Allergy |
C0171023 | A drug used to treat certain mental disorders. It is also being studied in the treatment of nausea and vomiting caused by some cancer treatments. It is a type of antipsychotic and a type of monoamine antagonist. | Olanzapine (substance)|2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine|Product containing olanzapine (medicinal product)|OLANZapine|olanzapine|OLANZAPINE|Olanzapinum|2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine|Olanzapina|Olanzapin|Olanzapine|Olanzapine-containing product | olanzapine |
C0027497 | An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses. | nausea symptoms|nausea symptom|Nausea (finding)|nauseating|nauseated|Nauseous|queasy|symptom nausea|Nausea|Observation of nausea|symptoms nausea|sick feeling|QUEASY|Nauseated|feel sick|NAUSEA|nausea|feeling sick|FEELING QUEASY|nauseas|nauseous | Nausea |
C0042963 | The forcible expulsion of the contents of the STOMACH through the MOUTH. | vomiting|emesis|Observation of vomiting|Vomiting symptom (finding)|Vomiting, NOS|Finding of vomiting (finding)|vomits|vomit|Throwing up|throw up|Vomiting|Emesis|throwing up|Finding of vomiting|Vomiting symptom|Vomiting (disorder)|VOMITING|vomited|EMESIS|vomiting symptoms|symptoms vomiting | Vomiting |
C0034826 | One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. | Receptor, Muscarinic Acetylcholine|Muscarinic Receptor|Receptor, Muscarinic|Receptors, Muscarinic|Muscarinic receptor site|Muscarinic Acetylcholine Receptors|Muscarinic receptor|Acetylcholine Receptor, Muscarinic|Muscarinic receptors|muscarinic receptor|Receptors, Muscarinic Acetylcholine|Muscarinic receptor (substance)|muscarinics receptors|muscarinic receptors|Muscarinic acetylcholine receptor|Muscarinic Acetylcholine Receptor|Acetylcholine Receptors, Muscarinic|Muscarinic Receptors | Muscarinic Acetylcholine Receptor |
C0153381 | A primary or metastatic malignant neoplasm involving the oral cavity. The majority are squamous cell carcinomas. | Malignant Neoplasm of Mouth|mouth cancers|Malignant Oral Neoplasm|cancer of mouth|Malignant tumour of mouth|Malignant neoplasm of oral cavity NOS|Oral Cancers|Malignant tumour of oral cavity|Malignant Oral Cavity Tumor|Cancer, Mouth|Malignant tumor of oral cavity|Cancer of oral cavity|Malignant neoplasm of mouth, NOS|CA - Mouth cancer|Malignant Oral Cavity Neoplasm|Malignant tumor of mouth|Malignant Mouth Neoplasm|Malignant Mouth Tumor|mouth cancer|Malignant Tumor of Mouth|Mouth cancer|Mouth Cancers|Oral Cancer|Cancers, Mouth|Cancer, Oral|oral cavity cancer|Mouth--Cancer|Cancers, Oral|Malignant Lip and Oral Cavity Neoplasm|Malignant neoplasm of mouth|Malignant neoplasm of mouth, unspecified|Cancer of the Mouth|Malignant Tumor of the Mouth|oral cancers|Cancer of Mouth|oral cancer|cancer of the mouth|Malignant Neoplasm of the Mouth|Malignant tumor of oral cavity (disorder)|Mouth Cancer | Malignant neoplasm of mouth |
C0221198 | A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part. | GROSS LESION|Visible Lesion|Lesion, NOS|lesion|Lesion|Lesion (morphologic abnormality)|lesions | Lesion |
C0549379 | The reemergence of a carcinoma after a period of remission. | Recurrent Carcinoma|Relapsed Cancer|cancer recurrent|Recurrent Cancer|recurrent cancer|Relapsed Carcinoma | Recurrent Carcinoma |
C0003392 | Substances that inhibit or prevent the proliferation of NEOPLASMS. | antineoplastic agents|Cancer Chemotherapy Agents|Chemotherapeutic Agents, Neoplastic Disease|Cancer Drug|Agents, Chemotherapeutic Anticancer|Anticancer Agents|Chemotherapy Drugs, Cancer|Antineoplastic agent|Antineoplastic agents|Antineoplastic agent, NOS|Antineoplastic|Antitumor Drugs|Antineoplastics|antitumor agent|Chemotherapeutic Anticancer Agents|antineoplastic drugs|Antineoplastic Drugs|Antineoplastic Agent|Drugs, Antineoplastic|agents antineoplastics|Drugs, Cancer Chemotherapy|Antineoplastic drug|chemotherapeutic agent|Drugs, Antitumor|Agents, Antitumor|Anti-Tumor Drugs|Antitumor Agents|antineoplastic agent|antineoplastics|Cancer Chemotherapy Drugs|agents antineoplastic|Agents, Anticancer|ANTINEOPLASTIC AGENTS|Drug, Chemotherapeutic Anticancer|ANTINEOPLASTICS|anti-neoplastic agents|Antiproliferative Agents|Agents, Cancer Chemotherapy|Antineoplastic Agents|Antineoplastic agent (substance)|Antiproliferative Drugs|antineoplastic drug|Antineoplastic Agent [TC]|Tumor-Specific Treatment Agents|antineoplastic|Anti-Cancer Agents|Medicinal product acting as antineoplastic agent (product)|Chemotherapy Agents, Cancer|Chemotherapeutic Anticancer Drug|Agents, Antineoplastic|Anti-Tumor Agents | Antineoplastic Agents |
C0030231 | Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) | Palliative Treatments|comfort care|therapy palliative|Palliative care (regime/therapy)|symptom management|care palliatives|palliative care|Symptom Management|Palliative Treatment|Treatment, Palliative|Palliative Supportive Care|Therapy, Palliative|palliative therapy|cares palliative|palliation|care palliative|Care, Palliative|Symptoms Management|Supportive Care, Palliative|Comfort Care|Treatments, Palliative|Palliative Therapy|Palliative care, NOS|Palliative care|Palliative Care|Palliative treatment|palliative treatment | Palliative Care |
C0333047 | null | Recessions|Recession|Recession (morphologic abnormality)|recession|Recession, NOS | Recession |
C0877373 | Cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. | cancer advanced|Advanced Cancer|advanced cancer | Advanced Malignant Neoplasm |
C1278911 | null | Entire lip (body structure)|Entire lip | Entire lip |
C1280389 | null | Entire lower lip (body structure)|Entire lower lip | Entire lower lip |
C0027530 | The part of a human or animal body connecting the HEAD to the rest of the body. | Cervical|necks|Neck structure|Necks|Neck, NOS|neck|Neck (volume)|Collum|neck anatomy|Neck|Neck structure (body structure)|NECK|neck structure | Neck |
C0950521 | An abbreviation for a chemotherapy combination used alone or with other therapies to treat breast cancer. It is also being studied in the treatment of other types of cancer. It includes the drugs cyclophosphamide, methotrexate, and fluorouracil. | cyclophosphamide-methotrexate-fluorouracil regimen|cyclophosphamide/fluorouracil/methotrexate|CMF chemotherapy protocol|CTX/5-FU/MTX|Cytoxan-Methotrexate-Fluorouracil Regimen|cyclophosphamide, fluorouracil, and methotrexate chemotherapy protocol|Cyclophosphamide/Fluorouracil/Methotrexate|CMF|cmf|CMF regimen|Oral Cyclophosphamide/Methotrexate/Fluorouracil|CMF Regimen | cyclophosphamide/fluorouracil/methotrexate protocol |
C0149925 | A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA). | Small Cell Neuroendocrine Carcinoma of Lung|SMALL CELL CANCER OF THE LUNG|Small Cell Neuroendocrine Carcinoma of the Lung|Small Cell Carcinoma of Lung|small cell carcinoma of the lung|Small Cell Cancer Of The Lung|oat cell cancer|LUNG CARCINOMA, SMALL CELL|Small cell carcinoma of lung|Carcinoma, Small Cell Lung|Oat cell carcinoma of lung (disorder)|Small cell carcinoma of lung (disorder)|Small Cell Lung Carcinoma|small cell lung cancer|cancer cell lung small|small cell lung carcinoma|lung cancer, small cell|Lung cancer, small cell|Oat Cell Lung Cancer|OAT CELL CARCINOMA OF LUNG|small cell carcinoma of lung|Lung Small Cell Carcinoma|lung cancer oat cell|SCLC - Small cell lung cancer|SMALL CELL CARCINOMA OF LUNG|small cell carcinoma|Oat cell carcinoma of lung|SCCL|LUNG CANCER, SMALL CELL CARCINOMA|Small cell lung cancer|SCLC|small cell lung cancer (SCLC)|Small cell lung carcinoma|sclc|PULMONARY SMALL CELL CARCINOMA <OAT CELL>|cancer cell lung oat|Small Cell Lung Cancer|SCLC1|oat cell lung cancer|oat cell carcinoma of lung|Oat Cell Carcinoma of Lung|PULMONARY SMALL CELL CARCINOMA OAT CELL|LUNG CARCINOMA, OAT CELL|Lung Small Cell Neuroendocrine Carcinoma|Small Cell Carcinoma of the Lung|Oat cell lung cancer | Small cell carcinoma of lung |
C0762659 | A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds. | Amrubicin|amrubicin|(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione|AMRUBICIN | amrubicin |
C0920425 | Any intervention for management of a malignant neoplasm. | Cancer Therapeutic Procedure|anticancer therapy|Malignant Neoplasm Treatment|Cancer Therapy|Malignant Neoplasm Therapy|cancer therapy|Cancer Treatment|cancer therapies | Cancer Therapeutic Procedure |
C0451615 | A lessening of pain following an intervention. | Giving pain relief|Pain relief|Pain Relief|pain relief|Pain relief (procedure)|Relieving pain | Pain relief |
C0596581 | Any fluoropyrimidine-based agent with potential antineoplastic activity. As an antimetabolite, a fluoropyrimidine interferes with pyrimidine utilization and incorporation into DNA and RNA. | fluoropyrimidine|fluoropyrimidines | Fluoropyrimidine |
C0392920 | application of the beneficial effects of drugs to control or cure neoplastic growth. | neoplasm/cancer chemotherapy|neoplasm chemotherapy|chemotherapy|chemo|Antineoplastic chemotherapy regimen|cancer chemotherapy|neoplasm/cancer pharmacotherapy|Antineoplastic chemotherapy regimen (regime/therapy)|Cancer chemotherapy|chemotherapy regimen|chemotherapy regimens|neoplasm pharmacotherapy|chemotherapies|cancer pharmacotherapy | Chemotherapy Regimen |
C1521750 | Treatment using more than one anticancer drug. | Chemotherapy, Combination|Drug Therapy, Combination|Combination Drug Therapy|combination chemotherapy|Combination Chemotherapy | Combination Chemotherapy |
C0281177 | The use of interleukin in the treatment of any disease or disorder. | interleukin therapy|Interleukin therapy|therapy, interleukin | Interleukin Therapy |
C0199975 | null | Interleukin-2 therapy|Interleukin-2 therapy (procedure)|il-2 therapy|Il-2 therapy | Interleukin-2 therapy |
C0007134 | A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. | Cancers, Renal Cell|carcinoma kidney|Nephroid Carcinomas|carcinoma cells renal|Adenocarcinomas, Renal Cell|Cancer, Renal Cell|Adenocarcinoma Of Kidney|Renal cell carcinoma - morphology|hypernephroid carcinomas|Renal cell adenocarcinoma|Renal Cell Adenocarcinoma|Cancer starting in small tubes in kidneys|carcinoma of kidney|renal adenocarcinoma|cancer cell renal|Kidney Adenocarcinoma|RCC|Carcinomas, Renal Cell|cell renal cancer|renal cell cancer|RENAL CELL CARCINOMA|Renal cell carcinoma|renal carcinoma|cancer cells renal|Adenocarcinoma of kidney|adenocarcinoma renal|Renal cell carcinoma (disorder)|Renal Cell Carcinoma|carcinomas renal|RENAL CARCINOMA|Carcinomas, Nephroid|adenocarcinoma of the kidney|Grawitz tumour|Carcinoma, Nephroid|Adenocarcinoma, Renal Cell|renal cell adenocarcinoma|adenocarcinoma of kidney|Adenocarcinoma, Renal|renal cell carcinoma, stage unspecified|Renal Cell Cancer|Adenocarcinoma Of Kidneys|Carcinoma, Renal Cell|Renal Cell Cancers|adenocarcinoma cells renal|Grawitz tumor|Nephroid Carcinoma|Kidney, Adenocarcinoma Of|Renal adenocarcinoma|Renal carcinoma|Adenocarcinoma of Kidney|Adenocarcinoma of kidney (disorder)|Adenocarcinoma of the Kidney|Renal cell carcinoma (morphologic abnormality)|Renal Adenocarcinomas|Adenocarcinomas, Renal|Renal cell carcinoma, NOS|Renal Cell Carcinoma, Stage Unspecified|CARCINOMA, RENAL CELL, MALIGNANT|kidney carcinoma|renal cell carcinoma|grawitz tumor|adenocarcinoma kidneys|kidney adenocarcinoma|RENAL CANCER, ADENOCARCINOMA|rccs|Hypernephroma|carcinoma renal|Renal Cell Adenocarcinomas|Renal Adenocarcinoma|rcc|hypernephroma|of kidney carcinoma|carcinoma cell renal|Kidneys, Adenocarcinoma Of|Renal Cell Carcinomas | Renal Cell Carcinoma |
C0022677 | The renal tubule portion that extends from the BOWMAN CAPSULE in the KIDNEY CORTEX into the KIDNEY MEDULLA. The proximal tubule consists of a convoluted proximal segment in the cortex, and a distal straight segment descending into the medulla where it forms the U-shaped LOOP OF HENLE. | Proximal Renal Tubules|Proximal convoluted renal tubule structure (body structure)|Renal Tubule, Proximal|proximal tubules|Tubulus contortus proximalis|Tubules, Proximal Kidney|Proximal Kidney Tubule|proximal convoluted tubule|Proximal convoluted tubule|Proximal convoluted renal tubule|Renal Tubules, Proximal|Tubules, Proximal Renal|Tubule, Proximal Kidney|Tubule, Proximal Renal|convoluted proximal tubules|Proximal convoluted renal tubule structure|Proximal Kidney Tubules|Proximal Renal Tubule|Kidney Tubule, Proximal|proximal tubule | Kidney Tubules, Proximal |
C0232805 | null | functions normal renal|normal renal function|Normal renal function (finding)|Renal function, normal|Normal renal function | Normal renal function |
C0023487 | An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. | Acute promyelocytic leukemia (clinical)|acute promyelocytic leukemia|promyelocytic leukemia|Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA|Acute myeloid leukaemia, PML/RAR-alpha|Acute Promyelocytic Leukemias|Acute myeloid leukemia, t(15;17)(q22;q11-12)|Acute promyelocytic leukemia, FAB M3 (disorder)|APL|AML with t(15;17)(q22;q12)|progranulocytic leukemia|M3 - Acute promyelocytic leukemia|Acute promyelocytic leukemia, t(15;17)(q22;q11-12)|Acute myeloid leukemia, PML/RAR-alpha|APML - Acute promyelocytic leukemia|fab m3|M3 ANLL|Acute promyelocytic leukaemia|Myeloid Leukemia, Acute, M3|ANLL, M3|Acute promyelocytic leukaemia, FAB M3|LEUKEMIA, PROMYELOCYTIC|APL - Acute promyelocytic leukaemia|LEUKEMIA, ACUTE PROMYELOCYTIC|Acute promyelocytic leukaemia, PML/RAR-alpha|Leukemia, Promyelocytic, Acute|APL - Acute promyelocytic leukemia|Promyelocytic Leukemia, Acute|FAB M3|Progranulocytic Leukemia|ACUTE PROMYELOCYTIC LEUKEMIA|Leukemia, Myeloid, Acute, M3|Leukemia, Acute Promyelocytic|APML - Acute promyelocytic leukaemia|Acute promyelocytic leukemia, PML/RAR-alpha|Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML/RARA|Leukemia, Progranulocytic|Acute myeloid leukaemia, t(15;17)(q22;q11-12)|Acute promyelocytic leukemia|Promyelocytic Leukemia|acute promyelocytic leukaemia|APML|Acute promyelocytic leukaemia (clinical)|Acute promyelocytic leukemia, t(15;17)(q22;q11-12) (morphologic abnormality)|AML M3|M3 acute promyelocytic leukemia|Acute Promyelocytic Leukemia with PML-RARA|Acute Promyelocytic Leukemia|Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)|M3 - Acute promyelocytic leukaemia|Acute promyelocytic leukemia, FAB M3|acute promyelocytic leukemia apl | Acute Promyelocytic Leukemia |
C0796117 | A syndrome that is considered as part of the spectrum of Wolf-Hirschhorn Syndrome variability. It maps to the short arm of chromosome 4, at 4p16. | Syndrome, Pitt-Rogers-Danks|pitts syndrome|pitt rogers danks syndrome|Pitt Rogers Danks Syndrome|Pitt-Rogers-Danks Syndrome|PRDS|PITT-ROGERS-DANKS SYNDROME|Pitt Syndrome|Syndromes, Pitt|Syndrome, Pitt|Mental Retardation, Unusual Facies, And Intrauterine Growth Retardation|PITT SYNDROME|Pitt Syndromes | Pitt-Rogers-Danks Syndrome |
C0004895 | In some animals, the jaws together with their horny covering. The beak usually refers to the bill of birds in which the whole varies greatly in form according of the food and habits of the bird. While the beak refers most commonly to birds, the anatomical counterpart is found also in the turtle, squid, and octopus. (From Webster, 3d ed & Storer, et al., General Zoology, 6th ed, p491, 755) | Beak structure|beak|Beak, NOS|Bill, NOS|beaks|Beak structure (body structure)|Beak|Bill|Beaks | Beak |
C0004204 | null | ATP Receptor|Receptor, ATP|ATP receptor|ATP Receptors|Receptors, ATP | ATP Receptors |
C1429839 | null | LH2 complex, beta-subunit, bacteria | B800-850 light-harvesting complex, beta-subunit, bacteria |
C1429839 | null | LH2 complex, beta-subunit, bacteria | B800-850 light-harvesting complex, beta-subunit, bacteria |
C0019569 | Congenital MEGACOLON resulting from the absence of ganglion cells (aganglionosis) in a distal segment of the LARGE INTESTINE. The aganglionic segment is permanently contracted thus causing dilatation proximal to it. In most cases, the aganglionic segment is within the RECTUM and SIGMOID COLON. | Megacolon, Congenital|Congenital aganglionic megacolon|Hirshsprungs disease|Enlarged colon lacking nerve cells|aganglionosis|disease hirschsprung|hirschsprung disease|disease hirschsprungs|Congenital Megacolon|Aganglionosis|HIRSCHSPRUNG DISEASE|Aganglionic Megacolon|MEGACOLON, AGANGLIONIC|Hirschsprung's disease|Hirschsprung's disease (disorder)|Congenital megacolon|Hirschsprung megacolon|diseases hirschsprung|aganglionic megacolon|MEGACOLON, CONGENITAL|Hirschsprung's Disease|Disease, Hirschsprung|hirschsprung's disease|congenital megacolon|Disease, Hirschsprung's|hirschsprungs disease|Hirschsprung disease|megacolon congenital|Macrocolon|disease hirschsprung's|Hirschsprung Disease|Aganglionic megacolon|MEGACOLON CONGENITAL|Megacolon, Aganglionic|Hirschsprungs Disease|pelvirectal achalasia|HD - Hirschsprung's disease | Hirschsprung Disease |
C0013819 | Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. | Electroencephalogram (EEG)|EEG, NOS|Electroencephalogram (procedure)|electroencephalogram|Electroencephalography|Electroencephalogram|EEG - Electroencephalography|ELECTROENCEPHALOGRAPHY|electroencephalography|EEG|Electroencephalogram, NOS|electroencephalograms|eeg electroencephalography|electroencephalography (EEG) | Electroencephalography |
C0024485 | Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. | Steady State Free Precession MRI|MR Tomography|Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance|MRI, NOS|MAGNETIC RESONANCE IMAGING|imaging magnetic nuclear resonance|MRI|Steady-State Free Precession MRI|NMR|Nuclear magnetic resonance|magnetic resonance imaging (MRI)|Magnetic resonance imaging - action (qualifier value)|MRI Scan|magnetic resonance imaging|MRI - Magnetic resonance imaging|Imaging, NMR|Magnetic Resonance Imaging Scan|nmr imaging|Imaging, Magnetic Resonance|NMR - Nuclear magnetic resonance|NMRI|Magnetic resonance study|Magnetic resonance technique|nuclear magnetic resonance imaging|MR - Magnetic resonance|Magnetic resonance imaging (procedure)|NMR Tomography|Nuclear Magnetic Resonance Imaging|Magnetic Resonance Imaging|Magnetic resonance imaging - action|Magnetic resonance imaging|NMR Imaging|MR Imaging|Tomography, MR|Magnetic resonance imaging, NOS|Tomography, NMR|Zeugmatography|NMR imaging | Magnetic Resonance Imaging |
C0043539 | Either of a pair of bones that form the prominent part of the CHEEK and contribute to the ORBIT on each side of the SKULL. | zygoma|cheekbone|Zygomatic bone|Zygomatic bone structure (body structure)|bones orbital|orbital bone|bone zygomatic|Malar Bone|Cheek-bone|Bone, Malar|Cheekbone|bone cheek|Bones, Malar|cheek bones|cheek bone|Cheek bone|zygomatic bone|Cheek Bones|Bones, Jugal|Malar|Bone, Jugal|Zygomas|Jugal Bone|Zygoma|cheek-bone|Malar Bones|Orbital bone|Jugal Bones|Bones, Cheek|Cheek Bone|Os zygomaticum|Zygomatic bone structure|Zygomatic Bone|Malar bone|malar|Bone, Cheek|malar bone | Zygomatic bone |
C1184482 | null | grooves|Sulcus|groove|Anatomical fissure|Groove | Groove |
C0678236 | A large group of diseases which are characterized by a low prevalence in the population. They frequently are associated with problems in diagnosis and treatment. | disease rare|Rare Disorder|rare disease|Rare disorder|Rare Diseases|Rare Disease|Rare diseases|rare diseases|Disease, Rare|diseases rare | Rare Diseases |
C0012236 | Congenital syndrome characterized by a wide spectrum of characteristics including the absence of the THYMUS and PARATHYROID GLANDS resulting in T-cell immunodeficiency, HYPOCALCEMIA, defects in the outflow tract of the heart, and craniofacial anomalies. | DiGeorge sequence|Hypoplasia of Thymus and Parathyroids|Familial Third and Fourth Pharyngeal Pouch Syndrome|DIGEORGE SYNDROME|Di George syndrome|Pharyngeal pouch syndrome|di george's syndrome|DiGeorge syndrome|Velo-Cardio-Facial Syndrome|DiGeorge Syndrome|pharyngeal pouch syndrome|Thymic hypoplasia syndrome|Syndrome, DiGeorge|Thymic Aplasia Syndrome|DI GEORGE SYNDROME|digeorge sequence|CHROMOSOME 22q11.2 DELETION SYNDROME|Catch22|thymic aplasia syndrome|digeorges syndrome|digeorge anomaly|Autosomal Dominant Opitz G-Bbb Syndrome|22q deletion syndrome|Third and fourth pharyngeal pouch syndrome|HYPOPLASIA OF THYMUS AND PARATHYROIDS|digeorge syndrome|22q Deletion Syndrome(s)|Agenesis of the parathyroid and thymus glands|di george syndrome|Third and Fourth Pharyngeal Pouch Syndrome|DGS1|Congenital thymic aplasia syndrome|DiGeorge's Syndrome|digeorge syndromes|22q- syndrome|syndrome di george|Digeorge's syndrome|DiGeorge Sequence|di georges syndrome|VCF|digeorge's syndrome|DiGeorge's syndrome|Third and fourth pharyngeal arch syndrome|Shprintzen Syndrome|CATCH22|Thymic-parathyroid aplasia|Velocardiofacial Syndrome|22q11.2 Deletion Syndrome|DiGeorge Anomaly|thymic hypoplasia|Sphrintzen|THIRD AND FOURTH PHARYNGEAL POUCH SYNDROME|Autosomal Dominant Opitz G Bbb Syndrome|Pharyngeal Pouch Syndrome|DiGeorge Syndrome Type 1|DGS | DiGeorge Syndrome |
C0741916 | null | cardiac defect|cardiac defects | Cardiac defects |
C0152021 | A heart disease that is present at birth. Representative examples include atrial septal defect, ventricular septal defect, tetralogy of Fallot, and patent foramen ovale. | Congenital heart disease (disorder)|Congenital heart disease, NOS|DISEASE HEART CONGENITAL (NOS)|HEART DISEASE CONGENITAL|Congenital heart disease NOS|congenital heart disorder|CHD - Congenital heart disease|congenital heart disease|Congenital heart disease|CONGENITAL HEART DISEASE|Abnormally shaped heart|Heart Diseases, Congenital|Congenital Heart Disease | Congenital heart disease |
C0574769 | null | Pathologic hair loss from scalp|Loss of scalp hair (finding)|Scalp alopecia|Scalp hair loss|Balding|BALDING|Missing scalp hair|hair loss scalp|Loss of scalp hair|balding|scalp hair loss|Alopecia of scalp | Loss of scalp hair |
C0015934 | Failure of a FETUS to attain expected GROWTH. | Fetal growth retardation|Fetal growth retardation (disorder)|Fetal growth retardation, unspecified, unspecified [weight]|Intrauterine growth retardation, IUGR|Fetal growth retardation, unspecified weight|Poor foetal growth state|FGR - Foetal growth retardation|fetal growth retardation|intrauterine growth retard|growth intrauterine retardation|Intrauterine Growth Restriction|Intrauterine growth retardation, NOS|growth intrauterine restriction|Fetal growth retardation, NOS|Prenatal growth deficiency|Poor foetal growth|Fetal growth retardation, unspecified|Prenatal growth retardation|Fetal Growth Retardation|iugr|Poor fetal growth|Prenatal onset growth retardation|Growth retardation, prenatal onset|Poor prenatal growth|microsomia|Prenatal-onset growth retardation|IUGR|iugrs|intrauterine growth retardation|Intrauterine growth failure|Intrauterine growth retardation (IUGR)|FGR - Fetal growth retardation|Poor fetal growth state|Fetal Growth Restriction|Foetal growth retardation, NOS|IUGR - Intrauterine growth retardation|prenatal growth disorder|intrauterine growth restriction|Foetal growth retardation|Intrauterine growth retardation|Fetal growth retardation, unspecified [weight]|poor fetal growth|Intrauterine Growth Retardation|Intrauterine growth restriction|Fetal growth restriction|Growth Retardation, Intrauterine|Microsomic baby|Microsomia|Prenatal growth failure|In utero growth retardation | Fetal Growth Retardation |
C0265220 | A pleiotropic disorder of human development that comprises hypothalamic HAMARTOMA; central and postaxial POLYDACTYLY; bifid EPIGLOTTIS; ANAL ATRESIA; and renal and other abnormalities. This disorder is associated with FRAMESHIFT MUTATIONS in the GLI3 gene which encodes the GLI3 protein, a KRUPPEL-LIKE TRANSCRIPTION FACTORS family member. | Syndrome, Hypothalamic Hamartoblastoma|Syndrome, Hall-Pallister|Syndromes, Hypothalamic Hamartoblastoma|CAVE Complex|Hall-Pallister Syndrome|Ano-cerebro-digital Syndrome|pallister hall syndrome|Complex, CAVE|Hypothalamic Hamartoblastoma Syndrome|Cerebroacrovisceral Early Lethality Complex|Complices, CAVE|Syndrome, Pallister-Hall|PHS|Pallister-Hall syndrome|Pallister-Hall Syndrome|Hypothalamic Hamartoblastoma Syndromes|Pallister Hall Syndrome|HYPOTHALAMIC HAMARTOBLASTOMA, HYPOPITUITARISM, IMPERFORATE ANUS, AND POSTAXIAL POLYDACTYLY|Pallister-Hall syndrome (disorder)|Hypothalamic Hamartoblastoma, Hypopituitarism, Imperforate Anus, and Postaxial Polydactyly|pallister-hall syndrome|Hamartoblastoma Syndromes, Hypothalamic|CAVE Complices|PALLISTER-HALL SYNDROME|Hall Pallister Syndrome|Hamartoblastoma Syndrome, Hypothalamic | Pallister-Hall syndrome |
C0010314 | An infantile syndrome characterized by a cat-like cry, failure to thrive, microcephaly, MENTAL RETARDATION, spastic quadriparesis, micro- and retrognathia, glossoptosis, bilateral epicanthus, hypertelorism, and tiny external genitalia. It is caused by a deletion of the short arm of chromosome 5 (5p-). | Syndromes, 5p Minus|cat's cry syndrome|chromosome 5p deletion syndrome|Cri-du-Chat Syndrome|Deletion Syndrome, 5p|cri du chat syndrome|cats cry syndrome|Syndrome, Chromosome 5p-|Cat-Cry Syndrome|Deletion Syndromes, 5p|Partial deletion of short arm of chromosome 5 syndrome|cat cry syndrome|CAT CRY SYNDROME|5p syndrome|5p Syndrome|Deletion of short arm of chromosome 5|Syndrome, 5p Deletion|cri du chats syndrome|Cat Cry Syndromes|Lejeune's syndrome|Chromosome 5p deletion syndrome|cri-du-chat syndrome|5p- Syndrome|Minus Syndromes, 5p|5p Minus Syndromes|5p Minus Syndrome|Chromosome 5p- Syndromes|cris du chat syndrome|Lejeune syndrome|Chromosome 5p- Syndrome|Cat Cry Syndrome|cry cat syndrome|5p partial monosomy syndrome|5p- Syndrome, Chromosome|5p- syndrome|5p- Syndromes, Chromosome|chat cri du syndrome|Syndromes, Crying Cat|Syndrome, 5p-|chat du cri syndrome|Cri-du-chat syndrome|5p Deletion Syndrome|Syndrome, Crying Cat|Syndromes, Cat Cry|Syndromes, Cri-du-Chat|cri-du-chat syndromes|Deletion of Short Arm of Chromosome 5 Syndrome|Syndrome, Cat Cry|chromosome 5 short arm deletion syndrome|Crying Cat Syndromes|Syndromes, Chromosome 5p-|5p Deletion Syndromes|crying cat syndrome|Cri-du-Chat Syndromes|Syndrome, 5p Minus|Syndromes, 5p Deletion|Chromosome 5 Short Arm Deletion Syndrome|5p partial monosomy syndrome (disorder)|Chromosomal imbalance syndrome, pair 5, deletion, short arm|Chromosome 5p Deletion Syndrome|Cri du Chat Syndrome|Deletion 5p syndrome|5P minus (partial) syndrome|5p- Syndromes|Crying Cat Syndrome|cat crying syndrome|5p Partial Monosomy Syndrome|Syndrome, Cri-du-Chat|CRI-DU-CHAT SYNDROME|Cri du chat syndrome|Cri Du Chat Syndrome|Minus Syndrome, 5p|5p minus syndrome|CHROMOSOME 5p DELETION SYNDROME | Cri-du-Chat Syndrome |
C0795845 | null | Duplication 12p|partial trisomy 12p|Trisomy 12p|trisomy 12p | Chromosome 12, 12p trisomy |
C0333714 | null | Reciprocal translocation (morphologic abnormality)|translocation reciprocal|Translocation, reciprocal|Reciprocal translocation|reciprocal translocation|Reciprocal Translocation | Reciprocal translocation |
C0220668 | An autosomal dominant connective tissue disorder caused by mutation(s) in the FBN2 gene, encoding fibrillin-2. It is characterized by contractures, arachnodactyly, scoliosis, micrognathia, and crumpled ears. | Congenital Contractural Arachnodactyly|Ear anomalies-contractures-dysplasia of bone with kyphoscoliosis|CCA|BEALS SYNDROME|Arthrogryposis, Distal, Type 9|CONTRACTURAL ARACHNODACTYLY, CONGENITAL|ARTHROGRYPOSIS, DISTAL, TYPE 9|Congenital contractural arachnodactyly|Beals syndrome|Arachnodactyly, contractural Beals type|Beals-Hecht syndrome|Contractures, multiple with arachnodactyly|Congenital contractural arachnodactyly (disorder)|CCA - Congenital contractural arachnodactyly|DA9|Contractural Arachnodactyly, Congenital|Beals Syndrome|Beal's syndrome | Congenital contractural arachnodactyly |
C0015295 | The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. | Coding DNA sequence|exon|Exon|exons | Exons |
C0851278 | null | null | Fingers not including thumb |
C0025958 | A congenital abnormality in which the CEREBRUM is underdeveloped, the fontanels close prematurely, and, as a result, the head is small. (Desk Reference for Neuroscience, 2nd ed.) | Micrencephaly|Microcephalies|micrencephaly|microcephalus|Microcephalus (disorder)|Microcephaly|microencephaly|micrencephala|Microcephalus|microcephalic|Nanocephaly|microcephaly|Microencephaly|microcephalies|MICROCEPHALY|microcephali | Microcephaly |
C0265211 | null | MARSHALL-SMITH SYNDROME|marshall smith syndrome|Marshall-Smith syndrome (disorder)|marshall-smith syndrome|MRSHSS|Accelerated skeletal maturation, facial dysmorphism, failure to thrive syndrome|Marshall-Smith syndrome | Marshall-Smith syndrome |
C0232466 | Impaired ability to eat related to problems gathering food and getting ready to suck, chew, or swallow it. [ISCA:eriggs] | Problems, Feeding|Poor feeding|Feeding problem (finding)|Feeding problem|Feeding difficulty|difficulty feeding|Difficulty feeding|Feeding Problem|feeding difficulties|feeding problem|Feeding Problems|Feeding problems|Feeding difficulties|difficulties feeding|feeding problems|FEEDING DIFFICULTY | Feeding difficulties |
C0021851 | A segment of the LOWER GASTROINTESTINAL TRACT that includes the CECUM; the COLON; and the RECTUM. | large bowel|Intestinum crassum|Large intestinal structure|Structure of large intestine|Large intestine|Large bowel, NOS|Large Bowel|Bowel, Large|large intestine|Large intestine, NOS|Large Intestine|LARGE INTESTINE: GENERAL TERMS|LARGE INTESTINE|Large intestinal|Intestine, Large|Structure of large intestine (body structure)|Large bowel | Large Intestine |
C1266121 | A benign tumor that consists chiefly of fibrous CONNECTIVE TISSUE, with variable numbers of MUSCLE CELLS forming portions of the neoplasm (From Stedman's, 27th ed). | myofibroma|Myofibroma (morphologic abnormality)|Myofibroma|Lipoleiomyoma|Myofibromas | Myofibroma (morphologic abnormality) |
C0949486 | A cancer gene that plays a role in the suppression of metastasis, a process whereby cancer spreads from one part of the body to another. | Suppressor Genes, Metastasis|Suppressor Gene, Metastasis|Genes, Metastasis Suppressor|Metastasis Suppressor Gene|Gene, Metastasis Suppressor | Metastasis Suppressor Genes |
C0686619 | The spread of a malignant neoplasm to the lymph nodes. | Metastatic Malignant Neoplasm to the Lymph Nodes|Metastasis to Lymph Node|Metastases to Lymph Nodes|lymph node metastasis|lymph metastases node|Metastatic malignant neoplasm to lymph node|lymph node metastases|Metastatic Tumor to Lymph Node|Metastatic malignant neoplasm to lymph node, NOS|Cancer metastatic to lymph nodes|Metastatic Neoplasm to the Lymph Node|Secondary and unspecified malignant neoplasm of lymph nodes, site unspecified|Secondary lymph node cancer|cancer lymph nodes secondary|Secondary and unspecified malignant neoplasm of lymph nodes|lymph metastases nodes|Secondary and unspecified malignant neoplasm of lymph nodes NOS|Secondary malignant neoplasm of lymph node (disorder)|Secondary malignant neoplasm of lymph node, NOS|Secondary malignancy of lymph nodes|lymph metastasis nodes|Metastatic Malignant Neoplasm in Lymph Node|metastases to lymph nodes|Metastatic Malignant Neoplasm in the Lymph Nodes | Secondary malignant neoplasm of lymph node |
C0279671 | A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis. | Cervical Squamous Cell Carcinoma|cancer cells cervix squamous|uterine cervical cancer, squamous cell carcinoma|Squamous Cell Carcinoma of the Uterine Cervix|epidermoid carcinoma of the cervix|Squamous cervical cancer|Cervix Squamous Cell Carcinoma|squamous cell cervical cancer|uterine cervix cancer, squamous cell carcinoma|Squamous Cell Carcinoma of Uterine Cervix|squamous cell carcinoma cervix|Cervical Squamous Cell Cancer|cervical cancer squamous cell|Uterine Cervix Squamous Cell Carcinoma|carcinoma cell cervix squamous|cervix cancer, squamous cell carcinoma|Squamous Cell Carcinoma of the Cervix|squamous cell cancer of the cervix|Squamous Cell Carcinoma of Cervix|squamous cell carcinoma cervical|cancer cell cervix squamous|carcinoma of the cervix, squamous cell|Cervical Squamous Cell Carcinoma, NOS|cervical cancer, squamous cell carcinoma|cervical squamous cell carcinoma|Squamous cell carcinoma of cervix|Squamous Cell Carcinoma of the Cervix Uteri|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Squamous cell carcinoma of cervix (disorder)|Squamous Cell Carcinoma of Cervix Uteri|Cervix Uteri Squamous Cell Carcinoma|squamous cell carcinoma of the cervix|cervical squamous cell cancer|cervical epidermoid carcinoma|cancer of the cervix, squamous cell | Cervical Squamous Cell Carcinoma |
C0079183 | A large family of regulatory proteins that function as accessory subunits to a variety of CYCLIN-DEPENDENT KINASES. They generally function as ENZYME ACTIVATORS that drive the CELL CYCLE through transitions between phases. A subset of cyclins may also function as transcriptional regulators. | cyclins|cyclin|Cyclins|Cyclin | Cyclins |
C1413595 | null | collagen type IX alpha 1 chain|COLLAGEN, TYPE IX, ALPHA-1|COL9A1 gene|CARTILAGE-SPECIFIC SHORT COLLAGEN|COLLAGEN, CARTILAGE-SPECIFIC SHORT|COL9A1|ALPHA-1(IX) COLLAGEN CHAIN | COL9A1 gene |
C1413595 | null | collagen type IX alpha 1 chain|COLLAGEN, TYPE IX, ALPHA-1|COL9A1 gene|CARTILAGE-SPECIFIC SHORT COLLAGEN|COLLAGEN, CARTILAGE-SPECIFIC SHORT|COL9A1|ALPHA-1(IX) COLLAGEN CHAIN | COL9A1 gene |
C0914914 | null | 2-FPhPIE | 2-(2-(3-(3-fluorophenyl)-3-phenylpropyl)-1H-imidazol-4-yl)ethanamine |
C0914914 | null | 2-FPhPIE | 2-(2-(3-(3-fluorophenyl)-3-phenylpropyl)-1H-imidazol-4-yl)ethanamine |
C0858952 | null | null | silence |
C0227353 | null | Colonic epithelium (body structure)|Epithelium of colon|Colonic epithelium|Colon epithelium | Colonic epithelium |
C0694999 | null | null | Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
C0694999 | null | null | Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
C1516924 | Changes in the regulation of the expression of gene activity without alteration of genetic structure. | Epigenetic Process|Epigenetic Mechanism|Epigenetic Processes|Epigenetic Change|Processes, Epigenetics|Process, Epigenetic|Epigenetics|Epigenetics Processes|Processes, Epigenetic | Epigenetic Process |
C0041365 | A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations. | Cancer Biomarkers|Markers, Tumor|Biomarkers, Cancer|Tumor markers|Tumor Marker|Tumor Markers|tumor markers|tumor marker | Tumor Markers |
C0927195 | The non-neoplastic connective tissue of an organ. | stromas|Non-neoplastic Connective Tissue|Stroma|stroma | Stroma |
C0398367 | Development of lesions in the lymph node characterized by infiltration of the cortex or paracortex by large collections of proliferating histiocytes and complete or, more often, incomplete necrosis of lymphoid tissue. | Kikuchi Necrotizing Lymphadenitis|Kikuchis Disease|Necrotising Lymphadenitis, Histiocytic|Kikuchi disease|Necrotizing Lymphadenitis, Histiocytic|Lymphadenitis, Histiocytic Necrotizing|kikuchi fujimoto disease|Disease, Kikuchi-Fujimoto|Nosocomial Kikuchis Disease|Kikuchi-Fujimoto's Disease|Histiocytic Necrotising Lymphadenitis|kikuchi's disease|Lymphadenitis, Kikuchi Necrotizing|Kikuchi Fujimoto's Disease|Nosocomial Kikuchi's Disease|Histiocytic Necrotising Lymphadenitides|kikuchis disease|Disease, Kikuchi's|Kikuchi's Disease|Kikuchi-Fujimotos Disease|Kikuchi's Disease, Nosocomial|Lymphadenitis, Histiocytic Necrotising|kikuchi disease|Lymphadenitides, Histiocytic Necrotising|Necrotising Lymphadenitides, Histiocytic|Histiocytic necrotizing lymphadenitis|Nosocomial Kikuchi Disease|Histiocytic necrotizing lymphadenopathy|Kikuchi-Fujimoto Disease|Histiocytic necrotising lymphadenopathy|Histiocytic Necrotizing Lymphadenitis|Histiocytic necrotizing lymphadenitis (disorder)|Necrotizing Lymphadenitis, Kikuchi|kikuchi-fujimoto disease|Disease, Kikuchi|Disease, Kikuchi-Fujimoto's|Kikuchi Disease|Histiocytic necrotising lymphadenitis|Kikuchi Fujimoto Disease | Histiocytic Necrotizing Lymphadenitis |
C0024204 | They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. | glands lymphatic|LYMPH NODES|nodes lymph|Lymphatic gland|Structure of lymph node|Lymph node|Lymph Gland|Nodes, Lymph|Lymphonodus|Nodus lymphoideus|lymph node|Lymph node, NOS|node lymph|Lymph gland|Lymphatic Gland|Lymph Node Structures|Structure of lymph node (body structure)|lymph gland|lymphatic gland|glands lymph|Lymph gland, NOS|Nodus lymphaticus|Reticuloendothelial System, Lymph Node|gland lymph|Lymph Nodes|lymphs nodes|Lymph Node|Lymph nodes|Node, Lymph|lymphs node|lymph nodes|Lymph node structure|Lymphatic gland, NOS|LYMPH NODE | lymph nodes |
C0024228 | Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS. | Lymphangiopathy, NOS|DISEASES OF THE LYMPHOID TISSUES|disorders lymphatic system|Disorder of lymphatics|Disorder of lymphatic system (disorder)|Disorder of lymphoid system (disorder)|Disease, Lymphatic|Disorder of lymphatic system|Disorder of lymphoid system|Lymphatic Disease|Disorders of lymph node and lymphatics (disorder)|disorder of lymphatic system|Lymphangiopathy|Diseases, Lymphatic|Lymphatic Diseases|Lymphatics--Diseases|Disorders of lymph node and lymphatics|lymphatic diseases|Lymphatic Disorders|Diseases of lymph node or lymph vessels|Disorder of lymphatics, NOS|lymphatic disorders|lymphatic system disorder|lymphatic disorder|lymphatic disease|Lymphatic disease | Lymphatic Diseases |
C0542553 | null | Lymph sample (specimen) | Lymph sample |
C1441506 | The procedure or activity of determining something by mathematical or logical methods. | Calculation technique|calculated|Calculate|CALCULATION|Calculation|Calculation technique (qualifier value)|Calculated | Calculation |
C0009013 | A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) | Cells, Clone|Clones|Clone (cell)|clone cell|Clone, NOS|Cell, Clone|Clone cells|clones|clone cells|Cloning|clone|cells cloning|cell clones|Cell Clone|clonings|cloned|Clone Cells|cell cloning|Clone Cell|Clone | Clone Cells |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.